November 28, 2016 - By Dolores Ford · 0 Comments
The stock of Benitec Biopharma Limited Ads (NASDAQ:BNTC) registered a decrease of 18.03% in short interest. BNTC’s total short interest was 15,000 shares in November as published by FINRA. Its down 18.03% from 18,300 shares, reported previously. With 6,700 shares average volume, it will take short sellers 2 days to cover their BNTC’s short positions. The short interest to Benitec Biopharma Limited Ads’s float is 0.27%. The stock closed at $1.55 during the last session. It is down 5.49% since April 25, 2016 and is downtrending. It has underperformed by 11.50% the S&P500.
Benitec Biopharma Limited is a biotechnology company. The company has a market cap of $13.63 million. The Firm is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property ; development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. It currently has negative earnings. The Company’s In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.
More notable recent Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on October 31, 2014, also Seekingalpha.com with their article: “Benitec’s DdRNAi Targeting Fight Against HIV” published on August 13, 2014, Benzinga.com published: “Arbutus Biopharma Taken Off Of Chardan’s Sell List” on June 16, 2016. More interesting news about Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) were released by: Barrons.com and their article: “Anglo American Mines for Profits” published on April 25, 2015 as well as Reuters.com‘s news article titled: “Benitec Biopharma says commenced strategic engagement with Nantventures” with publication date: October 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford